Drugs / tridecactide
tridecactide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04374032 | May → Oct 2020 | COVID-19 | Bosnalijek D.D | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03283397 | Mar 2019 → Jul 2023 | relapsing-remitting multiple sclerosis | Bosnalijek D.D | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tridecactide | “10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.” NCT03283397 ↗ |
| Known as | .alpha.-1-13-corticotropin, human | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108340 ↗ |
| Known as | .alpha.1-13-acth | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108340 ↗ |
| Known as | Tridecactida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108340 ↗ |
| Modality | Peptide | “neuropeptide combination of metenkefalin and tridecactide (EK-12)” NCT03283397 ↗ |